---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-209005"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:38:47.048407+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Phathom Q2 net loss $41.0M; PDUFA dates Oct/Nov 2023 for VOQUEZNA

## Summary
- Net loss $41.0M in Q2 2023, improved from $50.9M in Q2 2022.
- Cash $248.8M at June 30; $100M available from Hercules on Oct 1, $175M upon Erosive GERD approval.
- FDA PDUFA dates: Oct 30 for VOQUEZNA H. pylori packs; Nov 17 for Erosive GERD NDA.
- Completed public offering May 2023 with $141.4M net proceeds.
- Phase 3 PHALCON-NERD-301 completed; regulatory submission for Non-Erosive GERD on track H2 2023.

## SEC filing metadata
- accession: 0001193125-23-209005
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312523209005/0001193125-23-209005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312523209005/d491223d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-209005
- JSON: https://secwatch.observer/filing/0001193125-23-209005.json
- Plain text: https://secwatch.observer/filing/0001193125-23-209005.txt

## Key facts
- Earnings Releases
  Phathom Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income $41.0 million.
  - Period: the quarter ended June 30, 2023
  - Net income: $41.0 million
  - Result: reported results
  source text: Net loss for the second quarter ended June 30, 2023, was $41.0 million, compared to $50.9 million for second quarter 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783183/000119312523209005/0001193125-23-209005-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.